255 related articles for article (PubMed ID: 8911977)
1. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
Dills DG; Schneider J
Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R
Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
[TBL] [Abstract][Full Text] [Related]
3. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
Rosenstock J; Samols E; Muchmore DB; Schneider J
Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
[TBL] [Abstract][Full Text] [Related]
4. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
5. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
Riddle MC; Schneider J
Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
Tsumura K
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful.
Schade DS; Jovanovic L; Schneider J
J Clin Pharmacol; 1998 Jul; 38(7):636-41. PubMed ID: 9702849
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
11. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
12. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.
Holstein A; Plaschke A; Egberts EH
Diabetes Metab Res Rev; 2001; 17(6):467-73. PubMed ID: 11757083
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
[TBL] [Abstract][Full Text] [Related]
15. Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent.
Prescrire Int; 1998 Aug; 7(36):106-7. PubMed ID: 10342947
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
17. Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries.
Gomis R; Raptis SA; Ravella R
Endocrine; 2000 Aug; 13(1):117-21. PubMed ID: 11051055
[TBL] [Abstract][Full Text] [Related]
18. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
19. [Clinical efficacy of glimepiride].
Kaneko T; Sakamoto N
Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
[No Abstract] [Full Text] [Related]
20. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.
Goldberg RB; Holvey SM; Schneider J
Diabetes Care; 1996 Aug; 19(8):849-56. PubMed ID: 8842603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
